Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7778587 | 0.94 | ESR1 (0.63) | ESR1ESR2 | |
| SCHEMBL7458270 | 0.93 | ESR1 (0.68) | ESR1ESR2 | |
| SCHEMBL7452788 | 0.89 | ESR1 (0.52) | ESR1ESR2 | |
| SCHEMBL7469979 | 0.85 | LTA4H (0.51) | ESR1ESR2LTA4H | |
| SCHEMBL7749392 | 0.85 | LTA4H (0.61) | ESR1LTA4H | |
| SCHEMBL8708988 | 0.81 | ESR1 (0.67) | ESR1ESR2 | |
| SCHEMBL18951282 | 0.81 | ESR1 (0.70) | ESR1ESR2 | |
| SCHEMBL7443460 | 0.78 | LTA4H (0.77) | ESR1LTA4H | |
| SCHEMBL14970684 | 0.78 | LTA4H (0.82) | LTA4H | |
| SCHEMBL15257179 | 0.78 | LTA4H (0.82) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328521-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2003-07-23 | — | — | EP | claimed |
| EP-1204656-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | claimed |
| WO-2002034741-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-02 | — | — | WO | claimed |
| EP-1121125-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2001-08-08 | — | — | EP | claimed |
| WO-2001009116-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | claimed |
| WO-2000021535-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | claimed |
| EP-1357903-A2 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO b]THIOPHENE AND SALTS THEREOF | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1328521-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1204655-A2 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2002034741-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| US-20020013342-A1 | Treatment of central nervous system disorders with selective estrogen receptor modulators | BALES KELLY RENEE (US) | 2002-01-31 | — | — | US | disclosed |
| WO-2001085147-A2 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF | ELI LILLY AND COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1121125-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001009115-A2 | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6077852-A | ADMINISTERING TO THE PATIENT SUFFERING FROM ALZHEIMER'S DISEASE A SUBSTITUTED BENZOTHIOPHENE DERIVATIVE | ELI LILLY AND COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000021535-A1 | PHARMACEUTICAL FORMULATIONS FOR USE IN ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
| EP-0986556-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0975628-A1 | PREVENTION OF BREAST CANCER WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045287-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045286-A1 | PREVENTION OF BREAST CANCER WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013342-A1 | Treatment of central nervous system disorders with selective estrogen receptor modulators | ESR1, ESRRA, ESR2 | ESR1 1/4885ESR2 3/4885LTA4H 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.